[go: up one dir, main page]

ATE390138T1 - Dipyridamol enthaltende zusammensetzungen mit verlängerter freisetzung und verfahren zu deren herstellung - Google Patents

Dipyridamol enthaltende zusammensetzungen mit verlängerter freisetzung und verfahren zu deren herstellung

Info

Publication number
ATE390138T1
ATE390138T1 AT06250764T AT06250764T ATE390138T1 AT E390138 T1 ATE390138 T1 AT E390138T1 AT 06250764 T AT06250764 T AT 06250764T AT 06250764 T AT06250764 T AT 06250764T AT E390138 T1 ATE390138 T1 AT E390138T1
Authority
AT
Austria
Prior art keywords
formulation
extended release
dipyridamol
production
compositions containing
Prior art date
Application number
AT06250764T
Other languages
English (en)
Inventor
Minutza Leibovici
Itamar Kanari
Michael Fox
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Application granted granted Critical
Publication of ATE390138T1 publication Critical patent/ATE390138T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/60Salicylic acid; Derivatives thereof
    • A61K31/612Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/284Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846Poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT06250764T 2006-02-09 2006-02-13 Dipyridamol enthaltende zusammensetzungen mit verlängerter freisetzung und verfahren zu deren herstellung ATE390138T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US77225706P 2006-02-09 2006-02-09

Publications (1)

Publication Number Publication Date
ATE390138T1 true ATE390138T1 (de) 2008-04-15

Family

ID=36384355

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06250764T ATE390138T1 (de) 2006-02-09 2006-02-13 Dipyridamol enthaltende zusammensetzungen mit verlängerter freisetzung und verfahren zu deren herstellung

Country Status (13)

Country Link
US (1) US20070184110A1 (de)
EP (1) EP1820506B1 (de)
JP (1) JP2008534681A (de)
CN (1) CN101365453A (de)
AT (1) ATE390138T1 (de)
AU (1) AU2006337643A1 (de)
CA (1) CA2640472A1 (de)
DE (1) DE602006000819T2 (de)
DK (1) DK1820506T3 (de)
ES (1) ES2303314T3 (de)
IL (1) IL193023A0 (de)
PT (1) PT1820506E (de)
WO (1) WO2007092026A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009097156A1 (en) * 2008-02-01 2009-08-06 Barr Laboratories, Inc. Pharmaceutical capsules comprising extended release dipyridamole pellets
US20100069326A1 (en) * 2008-02-14 2010-03-18 Wasimul Haque Combination Therapies to Treat Cardio- and Cerebro-Vascular Disorders
WO2009100534A1 (en) * 2008-02-14 2009-08-20 Kardiatech, Inc. Combination therapy to treat vascular disorders
US20120141584A1 (en) * 2009-08-26 2012-06-07 Aptapharma, Inc. Multilayer Minitablets
CN101780037B (zh) * 2010-02-03 2011-11-16 南昌大学 双嘧达莫自乳化给药系统及其制备方法
CN101919822B (zh) * 2010-07-16 2013-10-23 钟术光 综合性能改善的片剂及其制备方法
LT2704698T (lt) * 2011-05-05 2019-11-25 Hennig Arzneimittel Gmbh&Co Kg Vaisto forma, skirta aktyvių ingredientų kontroliuojamam atpalaidavimui
SMT202100608T1 (it) * 2012-02-21 2021-11-12 Towa Pharmaceutical Europe S L Composizioni farmaceutiche orali di dabigatran etexilato
HUE054186T2 (hu) 2013-07-19 2021-08-30 Boehringer Ingelheim Vetmedica Gmbh Éterezett ciklodextrin-származékokat tartalmazó, tartósított, folyékony, vizes gyógyászati készítmény
CN103417494B (zh) * 2013-08-13 2015-12-23 杭州高成生物营养技术有限公司 一种以酒石酸作为主要成分的微丸
BR112016011111B1 (pt) 2013-12-04 2022-11-16 Boehringer Ingelheim Vetmedica Gmbh Composições farmacêuticas aprimoradas de pimobendan
CN105106225A (zh) * 2015-09-10 2015-12-02 石家庄市智同医药科技有限公司 一种复方双嘧达莫阿司匹林片剂及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3031450A (en) * 1959-04-30 1962-04-24 Thomae Gmbh Dr K Substituted pyrimido-[5, 4-d]-pyrimidines
DD146547A5 (de) * 1978-07-15 1981-02-18 Boehringer Sohn Ingelheim Arzneimittel-retardform mit unloeslichen poroesen diffusionshuellen
DE2831164A1 (de) * 1978-07-15 1980-01-24 Boehringer Sohn Ingelheim Arzneimittel-retardform mit unloeslichen poroesen diffusionshuellen
DE2950977A1 (de) * 1978-12-22 1980-07-10 Donald E Panoz Neue galenische zubereitungsform fuer die orale verabreichung von medikamenten mit programmierter besetzung, sowie verfahren zu ihrer herstellung
DE3000979A1 (de) * 1980-01-12 1981-07-23 Dr. Karl Thomae Gmbh, 7950 Biberach Neue dipyridamol-retardformen und verfahren zu ihrer herstellung
DE3124090A1 (de) * 1981-06-19 1983-01-05 Dr. Karl Thomae Gmbh, 7950 Biberach Neue orale dipyridamolformen
DE3576119D1 (de) * 1984-07-21 1990-04-05 Hoechst Ag Kombinationspraeparat aus pyrimido-pyrimidinen und o-acetylsalicylsaeure bzw. deren pharmakologisch vertraeglichen salzen und dessen verwendung.
DE3627423A1 (de) * 1986-08-13 1988-02-18 Thomae Gmbh Dr K Arzneimittel enthaltend dipyridamol oder mopidamol und o-acetylsalicylsaeure bzw. deren physiologisch vertraegliche salze, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung der thrombusbildung
US6376242B1 (en) * 1999-09-21 2002-04-23 Emory University Methods and compositions for treating platelet-related disorders using MPL pathway inhibitory agents
EP1093814A1 (de) * 1999-10-22 2001-04-25 Boehringer Ingelheim Pharma KG Verwendung von Dipyridamole oder Mopidamol zur Herstellung eines Medikaments für die Behandlung und Vorbeugung von fibrinabhängigen Mikrozirkulationstörungen
US20020028240A1 (en) * 2000-04-17 2002-03-07 Toyohiro Sawada Timed-release compression-coated solid composition for oral administration

Also Published As

Publication number Publication date
PT1820506E (pt) 2008-05-23
AU2006337643A1 (en) 2007-08-16
IL193023A0 (en) 2009-02-11
WO2007092026A1 (en) 2007-08-16
DE602006000819T2 (de) 2009-04-09
CA2640472A1 (en) 2007-08-16
HK1104791A1 (en) 2008-01-25
JP2008534681A (ja) 2008-08-28
EP1820506B1 (de) 2008-03-26
DK1820506T3 (da) 2008-07-07
DE602006000819D1 (de) 2008-05-08
CN101365453A (zh) 2009-02-11
ES2303314T3 (es) 2008-08-01
US20070184110A1 (en) 2007-08-09
EP1820506A1 (de) 2007-08-22

Similar Documents

Publication Publication Date Title
ATE390138T1 (de) Dipyridamol enthaltende zusammensetzungen mit verlängerter freisetzung und verfahren zu deren herstellung
CY1108700T1 (el) Συνθεσεις απελευθερωσης φαρμακου εστερα αλφα-υδροξυ οξεος και μεθοδοι χρησης
IL192670A (en) Carboxylic Acids of 1, 3-Dioxane, Process for Preparation, Pharmaceutical Preparations Containing and Using it for Medication
PE20070618A1 (es) Composicion farmaceutica que contiene rosiglitazona en el tratamiento de alzheimer
DE60006070D1 (de) Pyrazolcarbonsäurederivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen
IL195178A0 (en) 4,5-diphenyl-pyrimidinyl-oxy or-mercapto substituted carboxylic acids, method for the production and use thereof as medicaments
WO2007098128A3 (en) Phenylephrine-containing liquid formulations
WO2008063300A8 (en) Boronic acids and esters as inhibitors of fatty acid amide hydrolase
ATE460401T1 (de) 1,2,4,5-tetrahydro-3h-benzazepinderivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen
JP2007523049A5 (de)
MX2012003555A (es) Composicion farmaceutica que comprende acido graso omega-3 y derivado hidroxi de una estatina y metodos para usar la misma.
MY140514A (en) Triazolopyridine derivatives as inhibitors of lipases and phospholipases
PE20140960A1 (es) Formulaciones que comprenden un inhibidor de dpp4
ATE457719T2 (de) Pharmazeutische zusammensetzungen mit kontrollierter freisetzung für säurelabile arzneimittel
ITMI20020731A1 (it) Composizioni farmaceutiche per acido acetilsalicilico e oli omega-3
IT1362675B (it) N-idrossiammidi -sostituiti con gruppi triciclici come inibitori dell'istone deacelitasi,loro preparazione ed impiego in formulazioni farmaceutiche
FI20055568A0 (fi) Menetelmä karboksyylihappoesteriseoksien valmistamiseksi ja niiden käyttö
ATE471930T1 (de) 3-aminocarbazolverbindungen, pharmazeutische zusammensetzungen, die diese enthalten, und verfahren zu deren herstellung
AR060019A1 (es) Composicion farmaceutica, producto y metodo de tratamiento para un trastorno cognitivo y usos de un inhibidor de acetilcolinesterasa y un antagonista de 5- ht6 en la fabricacion de un medicamento para el tratamiento de un trastorno cognitivo
GEP20125464B (en) Dha esters and use thereof in treatment and prevention of cardiovascular disease
ATE425961T1 (de) Salze substituierter allophansaureester und deren verwendung in arzneimitteln
ZA200902451B (en) Process for the synthesis of derivatives of 3-amino-tetrahydrofuran-3-carboxylic acid and use thereof as medicaments
EP1968566A4 (de) Zusammensetzungen von cis-9, trans-11 konjugierter linolsäure und vaccensäure und ihre verwendungen
ATE462408T1 (de) Pharmazeutische zusammensetzungen, enthaltend valatograst, und verfahren zu deren herstellung
DE602005011326D1 (de) Feste pharmazeutische zusammensetzung mit donepezilhydrochlorid

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties